Preferred Name |
Rifaximin |
|
Synonyms |
RIFAXIMIN Rifaximin Xifaxan |
|
Definitions |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C61926 |
|
CAS_Registry |
80621-81-4 |
|
Chemical_Formula |
C43H51N3O11 |
|
code |
C61926 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
Contributing_Source |
CTRP FDA |
|
DEFINITION |
An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract. |
|
Display_Name |
Rifaximin |
|
FDA_UNII_Code |
L36O5T016N |
|
FULL_SYN |
RIFAXIMIN Rifaximin Xifaxan |
|
label |
Rifaximin |
|
Legacy Concept Name |
Rifaximin |
|
NCI_Drug_Dictionary_ID |
654589 |
|
PDQ_Closed_Trial_Search_ID |
654589 |
|
PDQ_Open_Trial_Search_ID |
654589 |
|
Preferred_Name |
Rifaximin |
|
prefixIRI |
Thesaurus:C61926 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0073374 |
|
subClassOf |